Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

Derek Y. Chiang, Augusto Villanueva, Yujin Hoshida, Judit Peix, Philippa Newell, Beatriz Minguez, Amanda C. LeBlanc, Diana J. Donovan, Swan N. Thung, Manel Solé, Victoria Tovar, Clara Alsinet, Alex H. Ramos, Jordi Barretina, Sasan Roayaie, Myron Schwartz, Samuel Waxman, Jordi Bruix, Vincenzo Mazzaferro, Azra H. Ligon & 5 others Vesna Najfeld, Scott L. Friedman, William R. Sellers, Matthew Meyerson, Josep M. Llovet

Research output: Contribution to journalArticle

332 Citations (Scopus)

Abstract

Hepatocellular carcinomas represent the third leading cause of cancer-related deaths worldwide. The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus or hepatitis C virus infection. To identify genetic mechanisms of hepatocarcinogenesis, we characterized copy number alterations and gene expression profiles from the same set of tumors associated with hepatitis C virus. Most tumors harbored 1q gain, 8q gain, or 8p loss, with occasional alterations in 13 additional chromosome arms. In addition to amplifications at 11q13 in 6 of 103 tumors, 4 tumors harbored focal gains at 6p21 incorporating vascular endothelial growth factor A {VEGFA). Fluorescence in situ hybridization on an independent validation set of 210 tumors found 6p21 high-level gains in 14 tumors, as well as 2 tumors with 6p21 amplifications. Strikingly, this locus overlapped with copy gains in 4 of 371 lung adenocarcinomas. Overexpression of VEGFA via 6p21 gain in hepatocellular carcinomas suggested a novel, noncell-autonomous mechanism of oncogene activation. Hierarchical clustering of gene expression among 91 of these tumors identified five classes, including "CTNNB1", "proliferation", "IFN-related", a novel class defined by polysomy of chromosome 7, and an unannotated class. These class labels were further supported by molecular data; mutations in CTNNB1 were enriched in the "CTNNB1" class, whereas insulin-like growth factor I receptor and RPS6 phosphorylation were enriched in the "proliferation" class. The enrichment of signaling pathway alterations in gene expression classes provides insights on hepatocellular carcinoma pathogenesis. Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic tnerapies.

Original languageEnglish
Pages (from-to)6779-6788
Number of pages10
JournalCancer Research
Volume68
Issue number16
DOIs
Publication statusPublished - Aug 15 2008

Fingerprint

Vascular Endothelial Growth Factor A
Hepatocellular Carcinoma
Neoplasms
Hepacivirus
Gene Expression
Chromosomes, Human, Pair 13
IGF Type 1 Receptor
Chromosomes, Human, Pair 7
Virus Diseases
Fluorescence In Situ Hybridization
Oncogenes
Transcriptome
Hepatitis B virus
Cluster Analysis
Phosphorylation
Clinical Trials
Mutation
Liver
Wounds and Injuries

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., ... Llovet, J. M. (2008). Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Research, 68(16), 6779-6788. https://doi.org/10.1158/0008-5472.CAN-08-0742

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. / Chiang, Derek Y.; Villanueva, Augusto; Hoshida, Yujin; Peix, Judit; Newell, Philippa; Minguez, Beatriz; LeBlanc, Amanda C.; Donovan, Diana J.; Thung, Swan N.; Solé, Manel; Tovar, Victoria; Alsinet, Clara; Ramos, Alex H.; Barretina, Jordi; Roayaie, Sasan; Schwartz, Myron; Waxman, Samuel; Bruix, Jordi; Mazzaferro, Vincenzo; Ligon, Azra H.; Najfeld, Vesna; Friedman, Scott L.; Sellers, William R.; Meyerson, Matthew; Llovet, Josep M.

In: Cancer Research, Vol. 68, No. 16, 15.08.2008, p. 6779-6788.

Research output: Contribution to journalArticle

Chiang, DY, Villanueva, A, Hoshida, Y, Peix, J, Newell, P, Minguez, B, LeBlanc, AC, Donovan, DJ, Thung, SN, Solé, M, Tovar, V, Alsinet, C, Ramos, AH, Barretina, J, Roayaie, S, Schwartz, M, Waxman, S, Bruix, J, Mazzaferro, V, Ligon, AH, Najfeld, V, Friedman, SL, Sellers, WR, Meyerson, M & Llovet, JM 2008, 'Focal gains of VEGFA and molecular classification of hepatocellular carcinoma', Cancer Research, vol. 68, no. 16, pp. 6779-6788. https://doi.org/10.1158/0008-5472.CAN-08-0742
Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Research. 2008 Aug 15;68(16):6779-6788. https://doi.org/10.1158/0008-5472.CAN-08-0742
Chiang, Derek Y. ; Villanueva, Augusto ; Hoshida, Yujin ; Peix, Judit ; Newell, Philippa ; Minguez, Beatriz ; LeBlanc, Amanda C. ; Donovan, Diana J. ; Thung, Swan N. ; Solé, Manel ; Tovar, Victoria ; Alsinet, Clara ; Ramos, Alex H. ; Barretina, Jordi ; Roayaie, Sasan ; Schwartz, Myron ; Waxman, Samuel ; Bruix, Jordi ; Mazzaferro, Vincenzo ; Ligon, Azra H. ; Najfeld, Vesna ; Friedman, Scott L. ; Sellers, William R. ; Meyerson, Matthew ; Llovet, Josep M. / Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. In: Cancer Research. 2008 ; Vol. 68, No. 16. pp. 6779-6788.
@article{0895b70991b344d59f6124406f869dd2,
title = "Focal gains of VEGFA and molecular classification of hepatocellular carcinoma",
abstract = "Hepatocellular carcinomas represent the third leading cause of cancer-related deaths worldwide. The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus or hepatitis C virus infection. To identify genetic mechanisms of hepatocarcinogenesis, we characterized copy number alterations and gene expression profiles from the same set of tumors associated with hepatitis C virus. Most tumors harbored 1q gain, 8q gain, or 8p loss, with occasional alterations in 13 additional chromosome arms. In addition to amplifications at 11q13 in 6 of 103 tumors, 4 tumors harbored focal gains at 6p21 incorporating vascular endothelial growth factor A {VEGFA). Fluorescence in situ hybridization on an independent validation set of 210 tumors found 6p21 high-level gains in 14 tumors, as well as 2 tumors with 6p21 amplifications. Strikingly, this locus overlapped with copy gains in 4 of 371 lung adenocarcinomas. Overexpression of VEGFA via 6p21 gain in hepatocellular carcinomas suggested a novel, noncell-autonomous mechanism of oncogene activation. Hierarchical clustering of gene expression among 91 of these tumors identified five classes, including {"}CTNNB1{"}, {"}proliferation{"}, {"}IFN-related{"}, a novel class defined by polysomy of chromosome 7, and an unannotated class. These class labels were further supported by molecular data; mutations in CTNNB1 were enriched in the {"}CTNNB1{"} class, whereas insulin-like growth factor I receptor and RPS6 phosphorylation were enriched in the {"}proliferation{"} class. The enrichment of signaling pathway alterations in gene expression classes provides insights on hepatocellular carcinoma pathogenesis. Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic tnerapies.",
author = "Chiang, {Derek Y.} and Augusto Villanueva and Yujin Hoshida and Judit Peix and Philippa Newell and Beatriz Minguez and LeBlanc, {Amanda C.} and Donovan, {Diana J.} and Thung, {Swan N.} and Manel Sol{\'e} and Victoria Tovar and Clara Alsinet and Ramos, {Alex H.} and Jordi Barretina and Sasan Roayaie and Myron Schwartz and Samuel Waxman and Jordi Bruix and Vincenzo Mazzaferro and Ligon, {Azra H.} and Vesna Najfeld and Friedman, {Scott L.} and Sellers, {William R.} and Matthew Meyerson and Llovet, {Josep M.}",
year = "2008",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-08-0742",
language = "English",
volume = "68",
pages = "6779--6788",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Focal gains of VEGFA and molecular classification of hepatocellular carcinoma

AU - Chiang, Derek Y.

AU - Villanueva, Augusto

AU - Hoshida, Yujin

AU - Peix, Judit

AU - Newell, Philippa

AU - Minguez, Beatriz

AU - LeBlanc, Amanda C.

AU - Donovan, Diana J.

AU - Thung, Swan N.

AU - Solé, Manel

AU - Tovar, Victoria

AU - Alsinet, Clara

AU - Ramos, Alex H.

AU - Barretina, Jordi

AU - Roayaie, Sasan

AU - Schwartz, Myron

AU - Waxman, Samuel

AU - Bruix, Jordi

AU - Mazzaferro, Vincenzo

AU - Ligon, Azra H.

AU - Najfeld, Vesna

AU - Friedman, Scott L.

AU - Sellers, William R.

AU - Meyerson, Matthew

AU - Llovet, Josep M.

PY - 2008/8/15

Y1 - 2008/8/15

N2 - Hepatocellular carcinomas represent the third leading cause of cancer-related deaths worldwide. The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus or hepatitis C virus infection. To identify genetic mechanisms of hepatocarcinogenesis, we characterized copy number alterations and gene expression profiles from the same set of tumors associated with hepatitis C virus. Most tumors harbored 1q gain, 8q gain, or 8p loss, with occasional alterations in 13 additional chromosome arms. In addition to amplifications at 11q13 in 6 of 103 tumors, 4 tumors harbored focal gains at 6p21 incorporating vascular endothelial growth factor A {VEGFA). Fluorescence in situ hybridization on an independent validation set of 210 tumors found 6p21 high-level gains in 14 tumors, as well as 2 tumors with 6p21 amplifications. Strikingly, this locus overlapped with copy gains in 4 of 371 lung adenocarcinomas. Overexpression of VEGFA via 6p21 gain in hepatocellular carcinomas suggested a novel, noncell-autonomous mechanism of oncogene activation. Hierarchical clustering of gene expression among 91 of these tumors identified five classes, including "CTNNB1", "proliferation", "IFN-related", a novel class defined by polysomy of chromosome 7, and an unannotated class. These class labels were further supported by molecular data; mutations in CTNNB1 were enriched in the "CTNNB1" class, whereas insulin-like growth factor I receptor and RPS6 phosphorylation were enriched in the "proliferation" class. The enrichment of signaling pathway alterations in gene expression classes provides insights on hepatocellular carcinoma pathogenesis. Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic tnerapies.

AB - Hepatocellular carcinomas represent the third leading cause of cancer-related deaths worldwide. The vast majority of cases arise in the context of chronic liver injury due to hepatitis B virus or hepatitis C virus infection. To identify genetic mechanisms of hepatocarcinogenesis, we characterized copy number alterations and gene expression profiles from the same set of tumors associated with hepatitis C virus. Most tumors harbored 1q gain, 8q gain, or 8p loss, with occasional alterations in 13 additional chromosome arms. In addition to amplifications at 11q13 in 6 of 103 tumors, 4 tumors harbored focal gains at 6p21 incorporating vascular endothelial growth factor A {VEGFA). Fluorescence in situ hybridization on an independent validation set of 210 tumors found 6p21 high-level gains in 14 tumors, as well as 2 tumors with 6p21 amplifications. Strikingly, this locus overlapped with copy gains in 4 of 371 lung adenocarcinomas. Overexpression of VEGFA via 6p21 gain in hepatocellular carcinomas suggested a novel, noncell-autonomous mechanism of oncogene activation. Hierarchical clustering of gene expression among 91 of these tumors identified five classes, including "CTNNB1", "proliferation", "IFN-related", a novel class defined by polysomy of chromosome 7, and an unannotated class. These class labels were further supported by molecular data; mutations in CTNNB1 were enriched in the "CTNNB1" class, whereas insulin-like growth factor I receptor and RPS6 phosphorylation were enriched in the "proliferation" class. The enrichment of signaling pathway alterations in gene expression classes provides insights on hepatocellular carcinoma pathogenesis. Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic tnerapies.

UR - http://www.scopus.com/inward/record.url?scp=53049086329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53049086329&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-0742

DO - 10.1158/0008-5472.CAN-08-0742

M3 - Article

VL - 68

SP - 6779

EP - 6788

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 16

ER -